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OBJECTIVES: Cost-effectiveness assessments in T2DM are commonly based on models 
that predict only primary cardiovascular events. This study aimed to assess the implications 
of incorporating secondary cardiovascular events on predicted cost-effectiveness. 
METHODS: Routine UK hospital data, between 2000 and 2005, were analyzed to 
quantify the cumulative incidence of ﬁ rst, second and third myocardial infarction (MI) or 
stroke events in T2DM subjects. Adjustments were made for out of hospital mortality and 
under-diagnosis of T2DM. Cardiovascular risk equations, used in a previously published 
cost-utility model, were re-calibrated, using the ratio of primary plus subsequent event to 
primary event, to predict subsequent MIs and strokes consistent with the observed UK 
data. The cost-effectiveness analysis compared two treatment strategies: A: 1st line met-
formin; 2nd line DPP-4 inhibitor add-on; 3rd line sulphonylurea add-on. B: 1st line metfor-
min; 2nd line sulphonylurea add-on; 3rd line thiazolidinedione add-on. RESULTS: Of the 
1,124,846 T2DM patients identiﬁ ed, 55,868 and 65,436 experienced primary MI and 
stroke events, respectively. There were 2159 (3.86%) and 185 (0.003%) second and third 
MI admissions, and 5808 (8.88%) and 755 (0.012%) second and third stroke admissions, 
respectively. Modelled risk multipliers of 1.04 for MI and 1.1 for stroke were required to 
predict cumulative incidence consistent with the UK data. Incorporating subsequent events 
had little impact on the cost-utility analysis with the ICER decreasing from £3129 to 
£3105 per quality adjusted life-year. More noteworthy, was the impact on cost per life-year 
gained, which decreased from £257,902 to £90,055, with subsequent events included. 
CONCLUSIONS: The inclusion of subsequent cardiovascular events in models of T2DM 
provides greater face validity but has little impact upon cost-effectiveness. Thus, economic 
assessments of therapies that modify glycaemic control, using models that do not incor-
porate subsequent MI and stroke events, are not signiﬁ cantly biased.
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OBJECTIVES: Two recent multicenter, comparator-controlled, open-label, randomized, 
parallel group clinical trials comparing exenatide with insulin glargine and with biphasic 
insulin aspart provided evidence of the short-term clinical proﬁ le of exenatide. The 
objective of this cost-effectiveness analysis was to use these results as the basis for long-
term projections to estimate the clinical and economic outcomes associated with exena-
tide treatment versus insulin glargine and versus biphasic insulin aspart in Portuguese 
health care setting. METHODS: The previously published and validated IMS Core 
Diabetes Model was used to project the long-term clinical and cost outcomes for a cohort 
deﬁ ned as the intention-to-treat (ITT) population of patients in the H8O-MC-GWAA 
and H8O-MC-GWAD clinical trials having a baseline BMI ≥ 35 kg/m2. Portuguese-
speciﬁ c direct medical costs data were used in the analysis to model outcomes over a 
35-year time horizon from the National Health Service perspective. RESULTS: Exena-
tide was associated with ICERs of c61,637 per life-year gained and c17,222 per QALY 
gained versus biphasic insulin aspart. Exenatide was also associated with ICERs of 
c53,275 per life-year gained and c14,697 per QALY gained versus insulin glargine from 
the National Health Service perspective. Results from 18 sensitivity analyses and two 
BMI subgroup analyses indicated a limited impact of baseline BMI on the ﬁ nal results. 
Results were sensitive to disutilities applied for excess BMI and nausea. Results were 
also sensitive to assumed insulin daily doses (IU) for insulin glargine and biphasic insulin 
aspart after the ﬁ rst year. CONCLUSIONS: The outcomes of this CEA and CUA were 
that exenatide has been projected to improve life expectancy and quality-adjusted life 
expectancy compared to both insulin glargine and to biphasic insulin aspart in patients 
with type 2 diabetes failing OADs. Based upon these results exenatide could be consid-
ered good value for money in Portugal regardless of baseline BMI levels.
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OBJECTIVES: To assess the long-term cost-effectiveness of treatment with liraglutide on 
top of standard therapy with glimepiride (SU) compared with rosiglitazone in people with 
type 2 diabetes. METHODS: The extensively published and validated CORE Diabetes 
Model was populated with the clinical data from LEAD-1 trial: liraglutide + SU vs. 
rosiglitazone + SU. The analysis was performed from the Czech health care services payer’s 
perspective. a 20-year time horizon was chosen to reﬂ ect the costs and outcomes of dia-
betes as these are often only seen in the later stages of the disease. The analysis used health 
state utility values from published sources to assess the effect of treatment on QALYs. 
The unit costs of treatment and complications were derived from published sources or 
based on expert opinion survey and ofﬁ cial tariff lists for health care services paid by 
public payer (insurance company). All ﬁ gures are shown in CZK and EUR (100 CZK = 
3.94 EUR). RESULTS: QALYs increased with liraglutide 1,2 mg + SU vs. SU + rosigli-
tazone 4 mg by 0.236. Total direct costs increased by CZK 45,679 (c1800) resulting in 
incremental costs per QALY of CZK 193,468 (c7623). The incremental cost-effectiveness 
ratio for liraglutide 1.8 mg + SU vs. SU + rosiglitazone 4 mg was estimated at CZK 
378,762 (c14,923) per QALY gained (QALYs increased by 0.270). Total costs (including 
indirect costs) increased by CZK 44,028 (c1735) and CZK 100,301 (c3952) resulting in 
an incremental cost per QALY gained of CZK 186,475 (c7347) and CZK 371,188 
(c14,624), respectively. CONCLUSIONS: Treatment with liraglutide added to a sulpho-
nylurea is a cost-effective intervention compared with adding rosiglitazone and is likely to 
represent good value for money in the Czech Republic setting.
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OBJECTIVES: Estimate the cost-effectiveness (CE) of Pregabalin (PGB) and Usual 
Care (UC) in refractory outpatients with pDPN treated in usual medical practice in 
Primary Care settings in Spain. METHODS: Data extracted from a 12-week non-
interventional study were used in the CE analysis. Previously, PGB naïve patients 
treated with UC or PGB, matched by age (+5 years), sex and pain intensity (+5 pts), 
refractory (≥40 VAS-MPQ) to previous treatment were selected. Patients could switch 
to PGB (monotherapy/add-on) or to UC other than PGB. Time horizon was 12 weeks. 
Effectiveness was expressed as quality-adjusted life-years (QALY) gain. The CEA 
included the perspectives of the NHS and society (2006), with results expressed as 
incremental cost-effectiveness ratio (ICER). Bootstrapping techniques (10,000 re-
samples) were used to obtain the probabilistic ICER, its 95% percentile conﬁ dence 
interval (CI) and the CE acceptability curve. Univariate probabilistic sensitivity analy-
sis was also performed. RESULTS: A total of 189 patients, 112 in PGB group and 77 
in UC were identiﬁ ed. Compared with UC, PGB was associated with higher QALY 
gain; 0.0406 ± 0.0343 versus 0.0285 ± 0.0350 (P = 0.598). Although drug costs were 
higher for PGB (c262 ± 132 vs. c66 ± 66, P < 0.001), overall total costs (c1368 ± 
1229 vs. c1258 ± 1474; P = 0.587), or health care costs (c628 ± 590 vs. c469 ± 420; 
P = 0.134) were similar, although due its observational design and small sample size, 
ICERs varied extensively from c5302 (95% CI: dominant; c144,105) for total costs 
to c14,381 (dominant; c115,648) for health care costs and c39,592 (dominant; 
c131,754) for drug costs. However, probabilistic analyses showed 79% to 84% of 
ICERs were below the threshold of c30,000/QALY. CONCLUSIONS: This study 
suggests that using PGB to treat refractory out-patients with pDPN in community 
medical practice in Spain is cost-effective compared to UC in majority of patients. It 
also highlights the burden of the disease and supports the availability of effective 
treatments available for patients not achieving pain relief from older therapies.
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OBJECTIVES: To compare, from the perspective of Statutory Health Insurance (SHI) 
in Germany, direct diabetes-related treatment costs (DTC) in T2D patients during the 
ﬁ rst year after initiation of a BOT with either of the long-acting insulin analogues 
GLA or DET, based on the results of a randomized controlled trial (RCT), the L2T3 
study [1]. METHODS: According to the study protocol of the 24-week RCT, GLA 
was administered once daily, DET [2] twice daily. The respective insulin consumption 
was extrapolated to 52 weeks via logarithmic regression. Due to proof of non-inferi-
ority in the L2T3 study, a cost-minimization analysis was conducted. DTC from the 
SHI perspective comprised insulin consumption, test strips, needles and lancets. In the 
base-case analysis, average values of all model parameters were applied. Taking a 
conservative approach, it was assumed that needles were changed daily (disadvantage 
for GLA). a new test strip and lancet were assumed for each blood glucose measure-
ment. In comprehensive sensitivity analyses (impact analysis, analysis of extremes, 
Monte Carlo simulation), the robustness of the base-case results was tested. RESULTS: 
The base-case analysis revealed savings of c767 in annual DTC per patient when using 
BOT with GLA (c1141) compared to DET (c1908). Of these savings, c517 (67%) fell 
upon insulin, c214 (28%) upon test strips and c36 (5%) upon lancets. Savings in 
favour of GLA turned out to be robust in the sensitivity analyses. Price and insulin 
consumption of DET had the highest impact on these savings. CONCLUSIONS: 
Initiation of a BOT with GLA in T2D patients after failure of oral antidiabetic therapy 
alone may lead to substantial savings for SHI compared to BOT with DET. 
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